journal
MENU ▼
Read by QxMD icon Read
search

Frontiers in Oncology

journal
https://www.readbyqxmd.com/read/28929085/the-potential-of-heavy-ion-therapy-to-improve-outcomes-for-locally-advanced-non-small-cell-lung-cancer
#1
Stephen G Chun, Timothy D Solberg, David R Grosshans, Quynh-Nhu Nguyen, Charles B Simone, Radhe Mohan, Zhongxing Liao, Stephen M Hahn, Joseph M Herman, Steven J Frank
No abstract text is available yet for this article.
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28929084/long-term-treatment-response-and-patient-outcomes-for-vestibular-schwannoma-patients-treated-with-hypofractionated-stereotactic-radiotherapy
#2
Mira A Patel, Ariel E Marciscano, Chen Hu, Ignacio Jusué-Torres, Rupen Garg, Arif Rashid, Howard W Francis, Michael Lim, Kristin J Redmond, Daniele Rigamonti, Lawrence R Kleinberg
PURPOSE: The aim of this study is to evaluate long-term treatment outcome and toxicities among vestibular schwannoma (VS) patients treated with hypofractionated stereotactic radiotherapy (HSRT). METHODS: 383 patients with unilateral VS treated with HSRT (25 Gy, five fractions) between 1995 and 2007 were retrospectively reviewed. Treatment failure was defined as requiring salvage microsurgery. Posttreatment new/progressive clinical symptoms or increases in baseline tumor volume (BTV) due to treatment effect or progression were noted...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28929083/emerging-therapies-for-stage-iii-non-small-cell-lung-cancer-stereotactic-body-radiation-therapy-and-immunotherapy
#3
REVIEW
Sameera S Kumar, Kristin A Higgins, Ronald C McGarry
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized cases. In unresectable NSCLC, chemoradiation has been the standard of care for the past three decades. Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and national clinical trials. Though initial studies showed a benefit to dose escalation, phase III studies examining dose escalation using standard fractionation or hyperfractionation have failed to show a benefit...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28929082/endocrine-therapy-of-estrogen-receptor-positive-breast-cancer-cells-early-differential-effects-on-stem-cell-markers
#4
Euphemia Y Leung, Marjan E Askarian-Amiri, Debina Sarkar, Carole Ferraro-Peyret, Wayne R Joseph, Graeme J Finlay, Bruce C Baguley
INTRODUCTION: Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or deprivation of estrogen, leads initially to inhibition of cell proliferation, followed after several months by the emergence of resistant sub-lines that are phenotypically different from the parental line...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28920053/smoking-and-lung-cancer-a-geo-regional-perspective
#5
REVIEW
Zahraa Rahal, Shaza El Nemr, Ansam Sinjab, Hassan Chami, Arafat Tfayli, Humam Kadara
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the most frequently diagnosed subtype of this morbid malignancy. NSCLC is causally linked to tobacco consumption with more than 500 million smokers worldwide at high risk for this fatal malignancy. We are currently lagging in our knowledge of the early molecular (e.g., genomic) effects of smoking in NSCLC pathogenesis that would constitute ideal markers for early detection. This limitation is further amplified when considering the variable etiologic factors in NSCLC pathogenesis among different regions around the globe...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28913179/management-of-elderly-patients-with-glioblastoma-after-ce-6
#6
Sunit Das, Albert H Kim, Susan Chang, Mitchel S Berger
No abstract text is available yet for this article.
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28913178/modeling-cancer-cell-growth-dynamics-in-vitro-in-response-to-antimitotic-drug-treatment
#7
Alexander Lorz, Dana-Adriana Botesteanu, Doron Levy
Investigating the role of intrinsic cell heterogeneity emerging from variations in cell-cycle parameters and apoptosis is a crucial step toward better informing drug administration. Antimitotic agents, widely used in chemotherapy, target exclusively proliferative cells and commonly induce a prolonged mitotic arrest followed by cell death via apoptosis. In this paper, we developed a physiologically motivated mathematical framework for describing cancer cell growth dynamics that incorporates the intrinsic heterogeneity in the time individual cells spend in the cell-cycle and apoptosis process...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28913177/big-data-in-designing-clinical-trials-opportunities-and-challenges
#8
Charles S Mayo, Martha M Matuszak, Matthew J Schipper, Shruti Jolly, James A Hayman, Randall K Ten Haken
Emergence of big data analytics resource systems (BDARSs) as a part of routine practice in Radiation Oncology is on the horizon. Gradually, individual researchers, vendors, and professional societies are leading initiatives to create and demonstrate use of automated systems. What are the implications for design of clinical trials, as these systems emerge? Gold standard, randomized controlled trials (RCTs) have high internal validity for the patients and settings fitting constraints of the trial, but also have limitations including: reproducibility, generalizability to routine practice, infrequent external validation, selection bias, characterization of confounding factors, ethics, and use for rare events...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28913176/propensity-score-matched-comparison-of-intensity-modulated-radiation-therapy-vs-stereotactic-body-radiation-therapy-for-localized-prostate-cancer-a-survival-analysis-from-the-national-cancer-database
#9
Anthony Ricco, Alexandra Hanlon, Rachelle Lanciano
PURPOSE: No direct comparisons between extreme hypofractionation and conventional fractionation have been reported in randomized trials for the treatment of localized prostate cancer. The goal of this study is to use a propensity score matched (PSM) analysis with the National Cancer Database (NCDB) for the comparison of stereotactic body radiation therapy (SBRT) and intensity modulated radiation therapy (IMRT) for organ confined prostate cancer. METHODS: Men with localized prostate cancer treated with radiation dose ≥72 Gy for IMRT and ≥35 Gy for SBRT to the prostate only were abstracted from the NCDB...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28913175/regulation-of-endoplasmic-reticulum-mitochondria-ca-2-transfer-and-its-importance-for-anti-cancer-therapies
#10
REVIEW
Gaia Pedriali, Alessandro Rimessi, Luigi Sbano, Carlotta Giorgi, Mariusz R Wieckowski, Maurizio Previati, Paolo Pinton
Inter-organelle membrane contact sites are emerging as major sites for the regulation of intracellular Ca(2+) concentration and distribution. Here, extracellular stimuli operate on a wide array of channels, pumps, and ion exchangers to redistribute intracellular Ca(2+) among several compartments. The resulting highly defined spatial and temporal patterns of Ca(2+) movement can be used to elicit specific cellular responses, including cell proliferation, migration, or death. Plasma membrane (PM) also can directly contact mitochondria and endoplasmic reticulum (ER) through caveolae, small invaginations of the PM that ensure inter-organelle contacts, and can contribute to the regulation of numerous cellular functions through scaffolding proteins such as caveolins...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28900608/comparative-analysis-of-microrna-expression-among-benign-and-malignant-tongue-tissue-and-plasma-of-patients-with-tongue-cancer
#11
Guilherme Rabinowits, Michaela Bowden, Ludmila M Flores, Sigitas Verselis, Victoria Vergara, Vickie Y Jo, Nicole Chau, Jochen Lorch, Peter S Hammerman, Tom Thomas, Laura A Goguen, Donald Annino, Jonathan D Schoenfeld, Danielle N Margalit, Roy B Tishler, Robert I Haddad
BACKGROUND: Identification of a microRNA (miRNA) pattern to be used as a biomarker for HNSCC is challenging given the heterogeneity of the disease and different methodologies used. To better define the field, we performed a prospective analysis of blood, tumor, and paired benign tissues in tongue squamous cell carcinoma (SCC) patients. METHODS: Plasma samples were collected prior to surgery, and paired tumor and benign tissue blocks were collected from tongue cancer resections...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28894699/lung-cancer-understanding-its-molecular-pathology-and-the-2015-who-classification
#12
REVIEW
Kentaro Inamura
Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28894698/paradigm-shift-toward-reducing-overtreatment-of-ductal-carcinoma-in-situ-of-breast
#13
REVIEW
Yasuaki Sagara, Wong Julia, Mehra Golshan, Masakazu Toi
The prevalence of ductal carcinoma in situ (DCIS) of the breast has increased substantially after the introduction of breast cancer screening programs, although the clinical effects of early DCIS detection and treatment remain unclear. The standard treatment for DCIS has involved local breast-conserving surgery (BCS) followed by radiotherapy (RT) or total mastectomy with/without endocrine therapy, and the choice of local treatment is not usually based on clinicopathologic or biological factors. However, we have investigated the effectiveness of local treatment using breast surgery and RT using Surveillance, Epidemiology, and End Results data, and found that the effectiveness of breast surgery was modified by the nuclear grade...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28894697/the-potential-role-of-senescence-as-a-modulator-of-platelets-and-tumorigenesis
#14
Claudio A Valenzuela, Ricardo Quintanilla, Rodrigo Moore-Carrasco, Nelson E Brown
In addition to thrombus formation, alterations in platelet function are frequently observed in cancer patients. Importantly, both thrombus and tumor formation are influenced by age, although the mechanisms through which physiological aging modulates these processes remain poorly understood. In this context, the potential effects of senescent cells on platelet function represent pathophysiological mechanisms that deserve further exploration. Cellular senescence has traditionally been viewed as a barrier to tumorigenesis...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28894696/quo-natas-danio-recent-progress-in-modeling-cancer-in-zebrafish
#15
REVIEW
Stefanie Kirchberger, Caterina Sturtzel, Susana Pascoal, Martin Distel
Over the last decade, zebrafish has proven to be a powerful model in cancer research. Zebrafish form tumors that histologically and genetically resemble human cancers. The live imaging and cost-effective compound screening possible with zebrafish especially complement classic mouse cancer models. Here, we report recent progress in the field, including genetically engineered zebrafish cancer models, xenotransplantation of human cancer cells into zebrafish, promising approaches toward live investigation of the tumor microenvironment, and identification of therapeutic strategies by performing compound screens on zebrafish cancer models...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28894695/which-obstacles-prevent-us-from-recruiting-into-clinical-trials-a-survey-about-the-environment-for-clinical-studies-at-a-german-university-hospital-in-a-comprehensive-cancer-center
#16
Christoph Straube, Peter Herschbach, Stephanie E Combs
BACKGROUND: Prospective clinical studies are the most important tool in modern medicine. The standard in good clinical practice in clinical trials has constantly improved leading to more sophisticated protocols. Moreover, translational questions are increasingly addressed in clinical trials. Such trials must follow elaborate rules and regulations. This is accompanied by a significant increase in documentation issues which require substantial manpower. Furthermore, university-based clinical centers are interested in increasing the amount of patients treated within clinical trials, and this number has evolved to be a key quality criterion...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28894694/evaluation-of-partial-breast-reirradiation-with-intraoperative-radiotherapy-after-prior-thoracic-radiation-a-single-institution-report-of-outcomes-and-toxicity
#17
Christine Chin, Priya Jadeja, Bret Taback, David P Horowitz, Sheldon M Feldman, Richard Ha, Eileen P Connolly
INTRODUCTION: Mastectomy is the current standard of care for ipsilateral breast tumor recurrences after prior whole breast irradiation (WBI). We report our single-institution experience with breast-conserving surgery (BCS) followed by intraoperative radiotherapy (IORT) as an alternative to salvage mastectomy for new or recurrent breast cancers that develop in the setting of prior thoracic radiation. METHODS: We performed an IRB-approved retrospective review of patients treated with breast IORT between September 2013 and November 2016...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28884088/oncolytic-viral-therapy-for-mesothelioma
#18
REVIEW
Daniel F Pease, Robert A Kratzke
The limited effectiveness of conventional therapy for malignant pleural mesothelioma demands innovative approaches to this difficult disease. Even with aggressive multimodality treatment of surgery, radiation, and/or chemotherapy, the median survival is only 1-2 years depending on stage and histology. Oncolytic viral therapy has emerged in the last several decades as a rapidly advancing field of immunotherapy studied in a wide spectrum of malignancies. Mesothelioma makes an ideal candidate for studying oncolysis given the frequently localized pattern of growth and pleural location providing access to direct intratumoral injection of virus...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28879168/the-oncopig-cancer-model-an-innovative-large-animal-translational-oncology-platform
#19
REVIEW
Kyle M Schachtschneider, Regina M Schwind, Jordan Newson, Nickolas Kinachtchouk, Mark Rizko, Nasya Mendoza-Elias, Paul Grippo, Daniel R Principe, Alex Park, Nana H Overgaard, Gregers Jungersen, Kelly D Garcia, Ajay V Maker, Laurie A Rund, Howard Ozer, Ron C Gaba, Lawrence B Schook
Despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide. More than 8.2 million deaths were attributed to cancer in 2012, and it is anticipated that cancer incidence will continue to rise, with 19.3 million cases expected by 2025. The development and investigation of new diagnostic modalities and innovative therapeutic tools is critical for reducing the global cancer burden...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28879167/vascular-endothelial-growth-factor-irradiation-and-axitinib-have-diverse-effects-on-motility-and-proliferation-of-glioblastoma-multiforme-cells
#20
Reinhardt Krcek, Veronika Matschke, Verena Theis, Irenäus Anton Adamietz, Helmut Bühler, Carsten Theiss
Glioblastoma multiforme (GBM) is the most common primary brain tumor. It is highly aggressive with an unfavorable prognosis for the patients despite therapies including surgery, irradiation, and chemotherapy. One important characteristic of highly vascularized GBM is the strong expression of vascular endothelial growth factor (VEGF). VEGF has become a new target in the treatment of GBM, and targeted therapies such as the VEGF-receptor blocker axitinib are in clinical trials. Most studies focus on VEGF-induced angiogenesis, but only very few investigations analyze autocrine or paracrine effects of VEGF on the tumor cells...
2017: Frontiers in Oncology
journal
journal
43752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"